



Bruce C. Robertson, PhD
Managing Director
H.I.G. BioVentures

Bruce Robertson is a Managing Director of H.I.G. BioVentures, the life science focused venture capital affiliate of H.I.G. Capital, a \$10 billion global private equity firm. H.I.G. BioVentures, which closed a new \$270 million fund in 2012, focuses on investment opportunities in biopharmaceuticals, medical devices, and diagnostics. He currently serves on the boards of Cerephex, CardioFocus, Apollo Endosurgery, and Clarus Therapeutics.

Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the BioLife Fund of Virginia's Center for Innovative Technology, and the University of Delaware Research Foundation.

Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund in Maryland, where he dealt with life science investments. During this time, Bruce invested in leading drug and device companies throughout the U.S. Before Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm that focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co. where he worked with medical devices.

Bruce holds a BSE in Chemical Engineering and a BA in Mathematics from the University of Pennsylvania, a PhD in Chemical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.